Signals
Prostate Cancer Value Starts Counting Cognition
ARACOG data presented at ASCO showed less cognitive decline with darolutamide than enzalutamide, bringing memory, attention and daily function into the prostate cancer treatment-value debate.
China’s Alzheimer’s Blood-Test Rollout Turns Diagnosis Into an Access Market
Alzheimer’s Blood Testing Moves Toward Routine Care
Oncology Trials Still Do Not Match the Patients They Will Treat
Cancer Pharmacogenomics Exposes an Ancestry Gap in Routine Testing
Biomarker Testing Is Rising, But Eligibility Still Gets Lost
Colon Cancer MRD Testing Is Nearing the Access Threshold
Breast Cancer Blood Tests Could Bring Treatment Decisions Earlier
Lung Cancer Screening Now Has a Diagnostic Bottleneck
Liquid Biopsy Turns Precision Oncology Into an NHS Delivery Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.